Españo Erica, Kim Dajung, Kim Jiyeon, Park Song-Kyu, Kim Jeong-Ki
Department of Pharmacy, Korea University College of Pharmacy, Sejong 30019, Korea.
Immune Netw. 2021 Feb 15;21(1):e7. doi: 10.4110/in.2021.21.e7. eCollection 2021 Feb.
The coronavirus disease 2019 (COVID-19) pandemic caused by the severe acute respiratory syndrome coronavirus 2 has severely impacted global health and economy. There is currently no effective approved treatment for COVID-19; although vaccines have been granted emergency use authorization in several countries, they are currently only administered to high-risk individuals, thereby leaving a gap in virus control measures. The scientific and clinical communities and drug manufacturers have collaborated to speed up the discovery of potential therapies for COVID-19 by taking advantage of currently approved drugs as well as investigatory agents in clinical trials. In this review, we stratified some of these candidates based on their potential targets in the progression of COVID-19 and discuss some of the results of ongoing clinical evaluations.
由严重急性呼吸综合征冠状病毒2引起的2019冠状病毒病（COVID-19）大流行对全球健康和经济造成了严重影响。目前尚无针对COVID-19的有效批准治疗方法；尽管疫苗已在多个国家获得紧急使用授权，但目前仅接种给高危人群，从而在病毒控制措施方面留下了空白。科学界、临床界和制药商已合作，通过利用目前已批准的药物以及临床试验中的研究药物，加速发现针对COVID-19的潜在疗法。在本综述中，我们根据这些候选药物在COVID-19进展中的潜在靶点对其中一些进行了分层，并讨论了正在进行的临床评估的一些结果。
